165 related articles for article (PubMed ID: 12060125)
21. [Immunophenotypic characteristics of multiple myeloma cells].
Li JL; Liu YR; Chang Y; Fu JY; Chen SS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Jun; 10(3):226-8. PubMed ID: 12513791
[TBL] [Abstract][Full Text] [Related]
22. [BUN, Bence Jones protein, and chromosomal aberrations predict survival in multiple myeloma].
Okada K; Oguchi N; Shinohara K; Tamura N; Ishii K; Noguchi Y; Hayashi S; Yamamoto H; Takeichi M; Fujimoto H; Shirota T; Hayashi T
Rinsho Ketsueki; 1997 Dec; 38(12):1254-62. PubMed ID: 9455144
[TBL] [Abstract][Full Text] [Related]
23. Multiple myeloma expressing CD19(+)CD56(-) phenotype.
Sahara N; Ihara M; Ono T; Tamashima S; Matsui H; Takeshita A; Ohno R
Am J Hematol; 2000 Aug; 64(4):311-3. PubMed ID: 10911386
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma.
Cerny J; Fadare O; Hutchinson L; Wang SA
Eur J Haematol; 2008 Jul; 81(1):65-9. PubMed ID: 18462256
[TBL] [Abstract][Full Text] [Related]
25. The incidence of DNA aneuploidy in multiple myeloma does not correlate with stage of disease.
Nowak R; Oelschlägel U; Range U; Mölle M; Ehninger G
Am J Clin Pathol; 1998 Feb; 109(2):226-32. PubMed ID: 9583896
[TBL] [Abstract][Full Text] [Related]
26. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
Okura M; Ida N; Yamauchi T
Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis.
Zhang L; Huang Y; Lin Y; Zhang A; Zou R; Xu H; Wang S
Hematology; 2022 Dec; 27(1):122-131. PubMed ID: 35068378
[TBL] [Abstract][Full Text] [Related]
28. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
[TBL] [Abstract][Full Text] [Related]
29. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
[TBL] [Abstract][Full Text] [Related]
30. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma.
Moreau P; Robillard N; Avet-Loiseau H; Pineau D; Morineau N; Milpied N; Harousseau JL; Bataille R
Haematologica; 2004 May; 89(5):547-51. PubMed ID: 15136217
[TBL] [Abstract][Full Text] [Related]
31. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma.
Damgaard T; Knudsen LM; Dahl IM; Gimsing P; Lodahl M; Rasmussen T
Leuk Lymphoma; 2009 Feb; 50(2):236-46. PubMed ID: 19235015
[TBL] [Abstract][Full Text] [Related]
32. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
33. Instability of immunophenotype in plasma cell myeloma.
Cao W; Goolsby CL; Nelson BP; Singhal S; Mehta J; Peterson LC
Am J Clin Pathol; 2008 Jun; 129(6):926-33. PubMed ID: 18480010
[TBL] [Abstract][Full Text] [Related]
34. Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease.
Perez-Andres M; Almeida J; Martin-Ayuso M; De Las Heras N; Moro MJ; Martin-Nuñez G; Galende J; Cuello R; Abuín I; Moreno I; Domínguez M; Hernandez J; Mateo G; San Miguel JF; Orfao A
Int J Cancer; 2009 Jan; 124(2):367-75. PubMed ID: 19003959
[TBL] [Abstract][Full Text] [Related]
35. Multiple myeloma without paraprotein.
Szücs J
Haematologia (Budap); 1970; 4(1):97-102. PubMed ID: 5522360
[No Abstract] [Full Text] [Related]
36. Prognostic significance of plasma cell morphology in multiple myeloma.
Carter A; Hocherman I; Linn S; Cohen Y; Tatarsky I
Cancer; 1987 Sep; 60(5):1060-5. PubMed ID: 3607725
[TBL] [Abstract][Full Text] [Related]
37. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
[TBL] [Abstract][Full Text] [Related]
38. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
39. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma.
Drach J; Gattringer C; Glassl H; Drach D; Huber H
Hematol Oncol; 1992; 10(2):125-34. PubMed ID: 1592363
[TBL] [Abstract][Full Text] [Related]
40. Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
Brenning G; Wibell L; Bergström R
Eur J Clin Invest; 1985 Oct; 15(5):242-7. PubMed ID: 3935453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
